Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

@article{Abildgaard2003ComparisonOF,
  title={Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.},
  author={Niels Abildgaard and Kim Brixen and Jens E. Kristensen and Erik Fink Eriksen and Johan Lanng Nielsen and Lene Heickendorff},
  journal={British journal of haematology},
  year={2003},
  volume={120 2},
  pages={
          235-42
        }
}
Increased osteoclastic bone resorption is the major causal factor of bone disease in multiple myeloma. Recently, non-invasive methods have been developed for the estimation of bone resorptive activity. To evaluate the biological sensitivity and clinical usefulness of five biochemical assays for measuring the C-terminal telopeptide of collagen I (ICTP) in serum (beta-Crosslaps ELISA and ICTP radioimmunoassay) and urinary creatinine-adjusted excretions of pyridinoline (PYR), deoxypyridinoline… CONTINUE READING
Highly Cited
This paper has 47 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Use of urinary markers in cancer setting: A literature review

Journal of bone oncology • 2015
View 8 Excerpts
Highly Influenced

Osteolytic lesions marker in multiple myeloma.

View 4 Excerpts
Highly Influenced

Multiple myeloma: is it time for biomarker-driven therapy?

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting • 2015